THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, April 23, 2021
AlzeCure Pharma AB announced that its drug candidate ACD440 for neuropathic pain achieved promising results from a phase Ib clinical trial.
FREMONT, CA: AlzeCure Pharma AB, a pharmaceutical firm developing an extensive portfolio of drug candidates for diseases impacting the central nervous system, with projects in Alzheimer's disease and pain, recently announced that its drug candidate ACD440 for neuropathic pain obtained promising results from a phase Ib clinical trial.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The outcomes, which were reported slightly ahead of schedule, show that ACD440, a TRPV1 antagonist and AlzeCures neuropathic pain drug nominee in the company's Painless platform, was able to offer positive proof-of-mechanism data, demonstrating analgesic efficacy in humans. When compared to placebo, the effects of ACD440 were significant. It was also well accepted as a topical gel on human skin, indicating that it would be a suitable candidate for more clinical development as a local treatment for neuropathic pain.
"We are very pleased that ACD440 was both well-tolerated and able to show good analgesic efficacy," said Johan Sandin, CSO at AlzeCure Pharma. "Neuropathic pain is an area with a huge unmet medical need and we believe that ACD440 could significantly improve the quality of life for patients suffering from neuropathic pain."
"The results from this completed proof-of-mechanism study show that ACD440 has very good characteristics and at the same time demonstrate the value of AlzeCure's broad portfolio of projects, which together with the company's strong cash position, provides a strong value proposition to both investors and pharma companies," said Martin Jonsson, CEO of AlzeCure. "We are now looking forward to taking ACD440 further into Phase II studies, which may also generate even greater out-licensing interest."
In December 2020, AlzeCure Pharma began a Phase Ib clinical trial with ACD440. More clinical trials and IND filings are in the works, with a Phase II trial scheduled in the second half of 2021.
More in News